An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

🤖 Plain-English Summary

Path to another drug against COVID-19 The rapid development of vaccines has been crucial in battling the ongoing COVID-19 pandemic. In a phase 1 clinical trial, the drug reached concentrations expected to inhibit the virus based on in vitro studies.

🔑 Key Findings

• However, access challenges remain, breakthrough infections occur, and emerging variants present increased risk.
• Developing antiviral therapeutics is therefore a high priority for the treatment of COVID-19.
• Some drug candidates in clinical trials act against the viral RNA-dependent RNA polymerase, but there are other viral enzymes that have been considered good targets for inhibition by drugs.

🔗 Related Resources